Immunonutrition-based solutions for diverse health applications

Publication ID: 24-11857525_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Immunonutrition-based solutions for diverse health applications,” Published Technical Disclosure No. 24-11857525_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857525_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,525.

Summary of the Inventive Concept

The inventive concept leverages the core technology of the original patent to develop novel applications and use cases in athletic performance, cognitive function, skin conditions, arthritis, and wound healing, demonstrating the versatility and broad potential of immunonutrition-based interventions.

Background and Problem Solved

The original patent addressed surgery-induced cachexia and expression of myeloid-derived suppressor cells and pro-inflammatory cytokines. However, the underlying technology has broader implications for human health. This inventive concept seeks to expand the application scope of immunonutrition supplements to tackle diverse health challenges, capitalizing on the benefits of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides.

Detailed Description of the Inventive Concept

The new claims encompass a range of innovative applications, including athletic performance optimization, cognitive function enhancement in individuals with attention deficit hyperactivity disorder, treatment of skin conditions, reduction of inflammation in arthritis, and improved wound healing. Each application leverages the immunonutrition supplement's ability to modulate the immune response, with tailored dosages and formulations to address specific health needs. The athletic performance system, for instance, provides between 5 g and 30 g of L-arginine per day, while the cognitive function method delivers 1.0 g to 5.0 g of eicosapentaenoic acid and docosahexaenoic acid in total per day.

Novelty and Inventive Step

The new claims introduce novel and non-obvious applications of the original patent's technology, demonstrating a significant expansion of its utility and scope. The inventive step lies in recognizing the potential of immunonutrition supplements to address diverse health challenges, and developing targeted formulations and dosages to achieve specific health benefits.

Alternative Embodiments and Variations

Alternative embodiments may include varying the ratio of L-arginine to omega-3 fatty acids, or incorporating additional nutrients to enhance the immunonutrition supplement's efficacy. Variations could also involve adapting the supplement for different delivery forms, such as injectables or oral capsules, to accommodate diverse patient needs and preferences.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential across various industries, including sports nutrition, cognitive health, dermatology, and wound care. The target market encompasses a broad range of consumers, from professional athletes to individuals seeking to improve their overall health and wellbeing.

Original Patent Information

Patent NumberUS 11,857,525
TitleTreatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines
Assignee(s)SOCIÉTÉ DES PRODUITS NESTLÉ S.A.